Company intelligence / Profile preview

Artera

Los Altos, California, United Statesartera.io ↗

Ownership: Private
Development stage: Commercial

Overview

The flagship product, the ArteraAI Prostate Test, is validated by multiple Phase 3 clinical trials and included in NCCN Guidelines. It predicts which patients with localized prostate cancer will benefit from therapy intensification such as androgen deprivation therapy. The test has been shown to improve risk stratification and support shared decision-making between clinicians and patients. Ongoing registry studies are measuring real-world impact on outcomes.

Therapeutic areas: Oncology
Modalities: Diagnostic test (AI-enabled)Digital pathology analysis
Industry: Pathology

Partnerships

American Cancer Society ("Improving Mortality from Prostate Cancer Together" initiative)PathNetCorePlus

Beyond the preview

Go deeper on Artera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artera.

Explore the full profile